Figure 5.
Assessment of phosphoS3291 antiserum specificity. Time course studies showing protein levels in indicated number of min after 10 nM E2 treatment (E2). Western blotting with phosphospecific BRCA2 antibody 1st panel incubated with either the non-phosphorylated peptide TFVSPAAQKAGG (2nd panel) or the phosphopeptide TFVSpPAAQKAGG (3rd panel). Bottom panel shows results of immunoprecipitation with pan-BRCA2 antibody followed by western blotting with S3291 phosphospecific antibody.